Literature DB >> 8603764

Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum.

E C Hoyt1, P K Lund, D E Winesett, C R Fuller, M A Ghatei, S R Bloom, M H Ulshen.   

Abstract

Intestinal proglucagon is thought to be synthesized primarily by the distal gut, although the role of proglucagon-derived glucagon-like peptide I (GLP-I) as a major physiological incretin would seem to be associated with production in proximal small bowel. To better characterize the sites of production of proglucagon and GLP-I in the small intestine and evaluate nutrient regulation of small bowel proglucagon and derived peptides, we evaluated the effects of fasting for 72 h and subsequent refeeding or jejunal infusion of long-chain triglyceride (LCT) for 24 h on local expression of proglucagon in proximal and distal small bowel. Proglucagon mRNA abundance and cellular localization were determined and correlated with wet weight of bowel. In jejunum, proglucagon mRNA abundance decreased by 40% with fasting (P < 0.005) and increased with refeeding to levels similar to those of ad libitum-fed animals. In ileum, fasting resulted in a 20% decrease in proglucagon mRNA (P < 0.005); in contrast to jejunum, refeeding did not result in a significant rise in ileal proglucagon mRNA abundance from fasting values. In jejunum, signal intensity of proglucagon mRNA per cell, determined by in situ hybridization, decreased with fasting (P < 0.05) and increased with refeeding (P < 0.005) in proportion to changes in mRNA abundance. Plasma enteroglucagon and GLP-I levels correlated with jejunal proglucagon mRNA. Intrajejunal infusion of LCT increased expression of proglucagon to a greater extent in jejunum than in ileum. In conclusion, enteral nutrient intake stimulates small bowel proglucagon expression; this effect is greater in jejunum than ileum, consistent with greater intraluminal nutrient exposure and the role of jejunum as a source of the major incretin GLP-I.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603764     DOI: 10.2337/diab.45.4.434

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Regulation of keratinocyte growth factor (KGF) and KGF receptor mRNAs by nutrient intake and KGF administration in rat intestine.

Authors:  C F Estívariz; L H Gu; S Scully; A Eli; C R Jonas; C L Farrell; T R Ziegler
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

Review 2.  GLP-1, the gut-brain, and brain-periphery axes.

Authors:  Cendrine Cabou; Rémy Burcelin
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells.

Authors:  Atsushi Suzuki; Hiromitsu Nakauchi; Hideki Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

4.  Distribution of prohormone convertase-6 expression in the gastrointestinal tract and effects of a fasting-refeeding regimen and a high-fat diet on ileal prohormone convertase-6 expression.

Authors:  V Udupi; G Gomez; I Lambertz; X Qi; J Reed; G H Greeley
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

5.  Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans.

Authors:  J Schirra; U Wank; R Arnold; B Göke; M Katschinski
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

6.  Protein hydrolysates stimulate proglucagon gene transcription in intestinal endocrine cells via two elements related to cyclic AMP response element.

Authors:  J-C Gevrey; M Malapel; J Philippe; G Mithieux; J-A Chayvialle; J Abello; M Cordier-Bussat
Journal:  Diabetologia       Date:  2004-04-14       Impact factor: 10.122

7.  Impact of diet-induced obesity on intestinal stem cells: hyperproliferation but impaired intrinsic function that requires insulin/IGF1.

Authors:  Amanda T Mah; Laurianne Van Landeghem; Hannah E Gavin; Scott T Magness; P Kay Lund
Journal:  Endocrinology       Date:  2014-06-10       Impact factor: 4.736

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.